United States

Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

4:02pm EDT
Change (% chg)

$-1.28 (-3.29%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Tue, May 15 2018

BRIEF-Biohaven Pharma Qtrly Loss Per Share $2.32

May 15 Biohaven Pharmaceutical Holding Company Ltd:

BRIEF-Biohaven Initiates Expanded Access Program For Sublingual BHV-0223

May 9 Biohaven Pharmaceutical Holding Company Ltd:

Biohaven plunges as investors pit migraine data against Allergan's drug

Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from Allergan's rival treatment.

Biohaven tumbles as migraine drug efficacy fails to impress investors

March 26 Biohaven Pharmaceutical Holding Co Ltd said its migraine treatment met the main goals in two late-stage studies but the efficacy data failed to differentiate when compared with rival treatments in a crowded field.

Select another date: